Dendreon Corporation has turned to experienced oncology leader John Johnson to jumpstart the commercial launch of Provenge (sipuleucel-T) in the U.S. and expand into Europe. The Seattle biotech announced the appointment of the former Savient Pharmaceuticals Inc. and ImClone Systems CEO to succeed Mitchell Gold Feb. 1, a move likely to be welcomed by investors though it came as a surprise.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?